Sangamo Brushes Off Phase IIb Diabetic Neuropathy Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech looks to new targets -- HIV and monogenic diseases -- after a disappointing trial in diabetic neuropathy.